Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 5/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 4/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | NQO2 | P16083 | 2/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | GABRP | O00591 | 1/20 | 0.32 |
| ▸ | GABRD | O14764 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6079952 | 0.89 | CYP4A11 (0.41) | CYP4A11CYP4F2TNKS2LCKNQO2 | |
| SCHEMBL6080526 | 0.84 | IGFBP5 (0.37) | TNKS2PIM1 | |
| SCHEMBL6080673 | 0.81 | NQO2 (0.39) | NQO2 | |
| SCHEMBL21044485 | 0.80 | CYP4A11 (0.56) | CYP4A11CYP4F2TNKS2NQO2CES1 | |
| SCHEMBL6080822 | 0.79 | RNASEH1 (0.44) | LCKPTGER4GABRPGABRDGABRA1 | |
| SCHEMBL6079179 | 0.77 | PPARG (0.44) | — | |
| SCHEMBL6080683 | 0.76 | NPC1 (0.40) | LCKPTGER4PIM1NPC1 | |
| SCHEMBL6080115 | 0.75 | MAPT (0.40) | LCKNQO2PTGER4 | |
| SCHEMBL6080554 | 0.75 | CYP4A11 (0.40) | CYP4A11CYP4F2LCKPTGER4GABRP | |
| SCHEMBL6079612 | 0.75 | CYP4A11 (0.40) | CYP4A11CYP4F2LCKPTGER4GABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | claimed |
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NQO1, NQO2, RECQL | CYP4A11 539/4885CYP4F2 300/4885TNKS2 1619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.